

## **IN THE CLAIMS**

Please amend the claims as follows. The following listing of claims replaces all prior versions.

1. (Currently amended) A hepatitis vaccine formulation comprising a bacteriophage particle the surface of which is unmodified and a pharmaceutically acceptable carrier therefor, the bacteriophage particle comprising a eukaryotic promoter and an exogenous nucleic acid molecule under control of the eukaryotic promoter and encoding a hepatitis virus polypeptide which is capable of expression and presentation on the surface of an antigen presenting cell of an organism, such that an immune response to said polypeptide is raised in the organism.

2. (Original) The hepatitis vaccine according to Claim 1 for use in vaccinating against hepatitis types A, B, C, D, and/or E.

3. (Previously Presented) The hepatitis vaccine according to Claim 1 wherein the antigen expressed and presented on the surface of the antigen presenting cell is a hepatitis surface antigen.

4. (Previously Presented) The hepatitis vaccine according to Claim 2 wherein the bacteriophage has been engineered to express more than one hepatitis antigen.

5. (Currently amended) A vaccine formulation comprising greater than  $10^9$  bacteriophage particles, the surface of each particle being unmodified, and a pharmaceutically acceptable carrier therefor, the bacteriophage particle comprising a eukaryotic promoter and an exogenous nucleic acid molecule under control of the eukaryotic promoter and encoding a hepatitis virus polypeptide which is capable of expression and presentation on the surface of an antigen presenting cell of an organism, such that an immune response to said polypeptide is raised in the organism.

6. (Previously Presented) The vaccine formulation according to Claim 5 which is capable of eliciting a humoral and/or cellular immune response.

7. (Original) The vaccine formulation according to claim 5 for use in vaccinating against a virus, bacterium, fungus, yeast, protozoan, helminth, insect or transmissible spongiform encephalopathy.

8. (Original) The vaccine formulation according to claim 5 for use in eliciting an immune response against a cancer cell by means of the expression of a cancer cell specific antigen.

9. (Currently amended) The vaccine formulation according to Claim 5 wherein the bacteriophage comprises transcriptional and/or translational regulators to facilitate expression of the polypeptide in addition to the eukaryotic promoter.

10. (Currently amended) The vaccine formulation according to claim ~~[[9]]~~5 wherein the eukaryotic promoter comprising a eukaryotic promoter such as the, is selected from the group consisting of a CMV, SV40, thymidine kinase [[or]] and RSV promoter.

11. (Original) The vaccine formulation according to claim 9 which comprises the exogenous nucleic acid under control of a constitutive promoter and a controllable promoter.

12. (Previously Presented) The vaccine formulation according to Claim 9 wherein the bacteriophage is lambda ( $\lambda$ ), p1 phage, T phage, Mu, fd, M13 or a filamentous phage.

13. (Previously Presented) The vaccine formulation according to Claim 9 wherein the bacteriophage is capable of expressing single or multiple copies of a polypeptide or a plurality of polypeptides.

14. (Previously Presented) The vaccine formulation according to Claim 9 wherein the bacteriophage is abortive to lytic growth in the natural bacterial flora of the chosen mammalian host.

15. (Previously Presented) The vaccine formulation according to Claim 9 further comprising inhibitors of lysosomal/endosomal enzymic catabolism and/or nuclear localisation signals.

16. (Previously Presented) The vaccine formulation according to Claim 9 further comprising an amount of the polypeptide to be expressed by the bacteriophage.

17. (Previously Presented) The vaccine formulation according to Claim 9 wherein the bacteriophage has been modified to express the polypeptide on the surface of the phage particle.

18. (Previously Presented) The vaccine formulation according to Claim 9 wherein the exogenous nucleic acid also encodes a polypeptide capable of augmenting the immune response.

19. (Previously Presented) The vaccine formulation according to Claim 9 further comprising an adjuvant.

20. (Previously Presented) The vaccine formulation according to Claim 9 wherein the bacteriophage is associated with a vehicle.

21. (Previously Presented) The vaccine formulation according to Claim 9 for use in the prophylaxis and/or treatment of a disease in a human or animal.

22. (Canceled).